Under new ownership after being acquired by GHO Capital, the company will consider expanding its business through acquisitions and moving into new geographies.
The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.
At the National Center for Quantitative Biology of Complex Systems, scientists hope mass spec will drive new biological questions and vice versa.
The firm is developing protein therapies incorporating synthetic amino acids coded for by "unnatural" base pairs developed at The Scripps Research Institute.
GHO, a London-based investment firm, purchased the company for an undisclosed amount from Chicago Growth Partners, Caprion's majority shareholder since 2012.
In Science this week: new chromatin imaging approach, and more.
University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.
Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.
Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.